{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 31,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 66,
  "notes": "The slide uses a numbered list to highlight key safety takeaways alongside detailed data tables.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/25",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.38,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Given every 12 hours for 7 days, GRX-917 was well-tolerated with no dose-limiting toxicities identified up to the highest dose of 300mg. 2. There were no serious adverse events reported nor dose-related discontinuations due to adverse events. 3. Adverse events in both single- and multiple-ascending dose (SAD and MAD) regimens were comparable to placebo-treated subjects. 4. No significant evidence of sedation or other benzodiazepine-like side effects at any doses tested.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63fc57b6-64de-45fa-a7d7-3d589b4f4503",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: TEAE = Treatment-emergent Adverse Event, SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. 1. n = number of subjects reporting at least one TEAE in that category, % = proportion of cohort total. 2. Defined as an adverse event that began after the start of trial medication treatment. 3. Non-exhaustive. Other recorded TEAEs included Upper respiratory tract infection (3%), Rash erythematous (3%), Dysmenorrhoea (3%), Catheter site pain (3%). 4. Of the 565 patients given XANAX in Ph.3 placebo-controlled trials for anxiety disorders, 41% reported drowsiness versus 22% of those administered placebo (as reported in XANAX FDA label).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "003da5bf-3bf1-4224-8dd2-56761ce5215d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.41,
        "y": 0.22
      },
      "kind": "table",
      "text": "GRX-917 Phase 1 MAD study safety data table showing TEAEs by dose cohort.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d3a84f7-6108-42b5-b582-b054c0ce0548",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Safe and well-tolerated, with sedation comparable to placebo and consistent with the EEG results on alpha power",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1972bf1d-862c-42f2-b496-42c55f03d39a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1 Study: GRX-917 Detailed Safety Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2bdaa04-0d8f-4a1b-870c-4e0f99e7223c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6ce87557-3898-455a-9820-a00131035347",
      "evidence": "GRX-917 Phase 1 MAD study safety data table showing TEAEs by dose cohort.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}